Kristi Rosa

Endotheliopathy represents a marker of progression to critical illness in patients with COVID-19 infection and soluble thrombomodulin segregates with mortality.

Treatment with the CAR T-cell product lisocabtagene maraleucel led to high response rates, with durable complete responses, in transplant-ineligible patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma who had poor prognostic features.

Imetelstat demonstrated meaningful and durable transfusion independence in patients with lower-risk myelodysplastic syndrome that are non-del(5q), dependent on red blood cell transfusion, and are relapsed/refractory to treatment with erythropoiesis-stimulating agents.

The Data and Safety Monitoring Board has advised that the phase 3 DUBLIN-3 trial of the antineoplastic agent plinabulin in patients with advanced or metastatic non–small cell lung cancer who have progressed on standard-of-care therapy can continue without any modifications.

The European Commission has approved encorafenib (Braftovi) in combination with cetuximab (Erbitux) for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer who have received prior systemic therapy.

The FDA has granted a priority review designation to a biologics license application for the investigational, humanized monoclonal antibody naxitamab (Danyelza) for the treatment of patients with relapsed/refractory high-risk neuroblastoma.

The addition of veliparib to cisplatin resulted in a significant improvement in progression-free survival and a trend toward improved overall survival in patients with BRCA-like triple-negative breast cancer.

The highly selective second-generation TKI alectinib demonstrated a clinically meaningful improvement in overall survival compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated promising clinical activity in patients with HER2-positive metastatic colorectal cancer, as well as in those with HER2-positive advanced gastric or gastroesophageal junction adenocarcinoma.

Fam-trastuzumab deruxtecan-nxki demonstrated favorable clinical activity with a high objective response rate and durable responses in patients with HER2-mutated non–small cell lung cancer.

Raymond Liu, MD, shed light on the benefits and challenges of utilizing telehealth in oncology and shared advice on how to implement this approach in practice.

Although little evidence exists with regard to how to best treat patients with breast cancer during the COVID-19 pandemic, guidelines have been issued by organizations like ESMO to assist providers with making those decisions.

Neeraj Agarwal, MD, provides insight into olaparib, further discusses the data that led to the regulatory approval, and shares the implications of this approval in metastatic castration-resistant prostate cancer.

Neeraj Agarwal, MD, provides insight into olaparib, further discussed the data that led to the regulatory approval, and shared the implications of this approval in metastatic castration-resistant prostate cancer.

Mary-Beth Percival, MD, provides insight into precautionary measures put into place to ensure patient safety, some of the considerations included in the paper, and the different ways in which she is overcoming challenges faced in practice in light of the pandemic.

John O. Mascarenhas, MD, discusses patient characteristics and outcomes following ruxolitinib discontinuation in myelofibrosis and research efforts being made to address a large unmet need in the space.

Mary-Beth Percival, MD, provides insight into precautionary measures put into place to ensure patient safety, some of the considerations included in the paper, and the different ways in which she is overcoming challenges faced in practice in light of the pandemic.

Nicholas J. Vogelzang, MD, discusses the significance of the rucaparib approval for this patient population.

Maria-Victoria Mateos, MD, PhD, discusses the data that led to the approval of the subcutaneous daratumumab formulation and the clinical implications of the regulatory decision.

Maria-Victoria Mateos, MD, PhD, discusses the data that led to the approval of the subcutaneous daratumumab formulation and the clinical implications of the regulatory decision.

Warner K. Huh, MD, discusses the management of gynecologic cancers during the COVID-19 era, the SGO COVID-19 task force, and what is needed to quell the pandemic, which he refers to as our version of the Great Depression.

Thomas Herzog, MD, discusses the FDA approval of olaparib plus bevacizumab for the frontline maintenance treatment of patients with homologous recombination deficiency–positive ovarian cancer.

Shannon N. Westin, MD, MPH, FACOG, discusses future directions in endometrial cancer.

COM701, a novel, first-in-class immune checkpoint inhibitor, was found to demonstrate encouraging preliminary antitumor activity and good tolerability when used as either a monotherapy and in combination with nivolumab in a number of heavily pretreated patients with advanced or metastatic solid tumors, according to data from a phase 1 trial.

Early data from TERAVOLT, a global registry collecting characteristics and outcomes of patients with thoracic cancers affected by COVID-19, suggested an unexpectedly high mortality among this patient population.

Treatment with atezolizumab in combination with vemurafenib and cobimetinib was found to significantly improve progression-free survival and produce durable responses versus vemurafenib and cobimetinib alone in treatment-naïve patients with BRAF V600–mutant advanced melanoma.

Rashmi Murthy, MD, MBE, discusses the data that led to the approval of the tucatinib triplet, the clinical implications of the approval on practice, and the next steps for research with the agent.

Balazs Halmos, MD, MS, provides insight on preventive measures put in place at his institution, day-to-day challenges faced in practice, and how he is staying connected with the broader community to share information.

As the COVID-19 pandemic beats down on major cities like New York, oncologists across the United States are either bracing themselves for what will hopefully be a peak in cases or desperately preparing for when the storm will hit their own health systems.

The addition of trastuzumab to carboplatin and paclitaxel resulted in a significant survival benefit in women with advanced or recurrent, HER2-positive uterine serous carcinoma, with the greatest benefit observed in those with stage III/IV disease who received the regimen up front.